Riociguat for pulmonary arterial hypertension associated with congenital heart disease

OBJECTIVE: The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenkranz, Stephan, Ghofrani, Hossein-Ardeschir, Beghetti, Maurice, Ivy, Dunbar, Frey, Reiner, Fritsch, Arno, Weimann, Gerrit, Saleh, Soundos, Apitz, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Pulmonary Vascular Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680166/
https://www.ncbi.nlm.nih.gov/pubmed/26135803
http://dx.doi.org/10.1136/heartjnl-2015-307832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680166/
https://www.ncbi.nlm.nih.gov/pubmed/26135803
http://dx.doi.org/10.1136/heartjnl-2015-307832

Ejemplares similares